Posts

New project started: ‘Prioritisation and risk evaluation of medicines in the environment’ (PREMIER)

The Innovative Medicines Initiative (IMI) project PREMIER aims to develop a centralised, user-friendly digital assessment system accessible for all relevant stakeholders. PREMIER will also explore options to incorporate environment considerations earlier in the drug development process to inform drug design and to reduce the need of animal testing. ECT is involved in this project as […]

Prioritisation and risk evaluation of medicines in the environment (PREMIER)

The Innovative Medicines Initiative (IMI) project ‘Prioritisation and risk evaluation of medicines in the environment’ (PREMIER) aims to develop a centralised, user-friendly and transparent digital assessment system accessible for all relevant stakeholders such as regulatory agencies, pharmaceutical industry, water managers and environmental non-governmental organisations. Furthermore, PREMIER will explore the options to incorporate environment considerations earlier […]

Intelligence-led Assessment of Pharmaceuticals in the Environment (iPiE)

Active pharmaceutical ingredients (APIs) of medicines for human use can be released to the environment during the manufacturing process, following use by patients or when unused medicines are disposed of in an incorrect manner. As APIs are biologically active compounds, concerns have been raised about the potential effects of APIs in the environment on human […]

Potential substances of very high concern based on environmental protection criteria of the REACH regulation: Verification by substance properties and prioritisation by relevance criteria

The REACH Regulation No. 1907/2006 introduced the concept of substances of very high concern (SHVC; Art. 57) for the control of risks to human health and the environment. In this project, the focus was on environmental concerns according to Art. 57(d) to 57(f): • Persistent, bioaccumulating and toxic substances (PBT; Art. 57(d)) • Very persistent and […]